Claims for Patent: 8,183,274

Summary for Patent: 8,183,274

Title:	Treatment of hyperproliferative disorders with diarylhydantoin compounds
Abstract:	The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Inventor(s):	Sawyers; Charles L. (New York, NY), Jung; Michael E. (Los Angeles, CA), Chen; Charlie D. (Shanghai, CN), Ouk; Samedy (Costa Mesa, CA), Tran; Chris (New York, NY), Wongvipat; John (Nanuet, NY)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	12/708,523
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,183,274
Patent Claims:	1. A method for treating prostate cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of ##STR00238## or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the prostate cancer. 2. The method of claim 1, wherein the compound is administered at a dosage in the range of from about 0.001 mg per kg body weight per day to about 100 mg per kg body weight per day. 3. The method of claim 1, wherein the compound is administered at a dosage in the range of from about 1 mg per kg body weight per day to about 10 mg per kg body weight per day. 4. The method of claim 1, wherein the compound is administered at a dosage in the range of from about 0.1 mg per kg body weight per day to about 10 mg per kg body weight per day. 5. The method of claim 1, wherein the compound is administered at a dosage of about 1 mg per kg body weight per day. 6. The method of claim 1, wherein the prostate cancer is hormone refractory prostate cancer. 7. The method of claim 1, wherein the compound is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, topically, or nasally. 8. The method of claim 1, wherein the compound is administered orally. 9. The method of claim 1, wherein the compound is administered in a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill. 10. The method of claim 1, wherein the compound is administered in a form selected from the group consisting of a capsule, tablet, and pill. 11. The method of claim 1, wherein the prostate cancer is hormone sensitive prostate cancer. 12. The method of claim 1, wherein the compound is ##STR00239## 13. The method of claim 1, wherein the compound is administered with a pharmaceutically acceptable carrier or diluent. 14. The method of claim 13, wherein the pharmaceutically acceptable carrier or diluent comprises one or more of dimethylsulfoxide (DMSO), polyethylene glycol (PEG), and water. 15. The method of claim 1, wherein the compound is administered at a dosage of about 2 mg per kg body weight per day. 16. The method of claim 1, wherein the compound is administered to achieve a peak plasma concentration in the range of from about 0.5 .mu.M to about 75 .mu.M. 17. The method of claim 1, wherein the compound is administered to achieve a peak plasma concentration of about 10 .mu.M. 18. The method of claim 1, wherein the compound is administered to achieve a steady state plasma concentration of from about 5 .mu.M to about 100 .mu.M. 19. The method of claim 1, wherein the compound is administered to achieve a steady state plasma concentration of from about 10 .mu.M to about 50 .mu.M. 20. The method of claim 1, wherein the compound is administered to achieve a steady state plasma concentration of about 25 .mu.M. 21. The method of claim 1, wherein the compound is administered daily. 22. The method of claim 1, wherein the compound is administered three times per day. 23. The method of claim 1, wherein the compound is administered in a unit dosage form comprising from about 5 mg to about 1000 mg of active ingredient per unit dosage form. 24. The method of claim 1, wherein the compound is administered in a unit dosage form comprising about 100 mg of active ingredient per unit dosage form. 25. A method for treating benign prostate hyperplasia comprising administering a therapeutically effective amount of a compound selected from the group consisting of ##STR00240## or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the benign prostate hyperplasia. 26. The method of claim 1, wherein the compound is ##STR00241## 27. The method of claim 1, wherein the compound is ##STR00242## 28. The method of claim 25, wherein the compound is ##STR00243## 29. The method of claim 25, wherein the compound is ##STR00244## 30. The method of claim 25, wherein the compound is ##STR00245## 31. The method of claim 12, wherein the prostate cancer is hormone refractory prostate cancer. 32. The method of claim 12, wherein the prostate cancer is hormone sensitive prostate cancer. 33. A method for treating breast cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of ##STR00246## or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the breast cancer. 34. The method of claim 33, wherein the compound is ##STR00247## 35. The method of claim 33, wherein the compound is ##STR00248## 36. The method of claim 33, wherein the compound is ##STR00249## 37. A method for treating ovarian cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of ##STR00250## or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the ovarian cancer. 38. The method of claim 37, wherein the compound is ##STR00251## 39. The method of claim 37, wherein the compound is ##STR00252## 40. The method of claim 37, wherein the compound is ##STR00253##